Npj Pre Oncol: a new combination therapy or a successful treatment for malignant ovarian cancer
Release date: 2017-05-05
Recently, a research report published in the international journal npj Precision Oncology, researchers from the University of California, Los Angeles, and other institutions have explained why 85% of female patients still have standardized chemotherapy after taking drug carboplatin. Following a recurrence of high-grade serous ovarian cancer, high-grade serous ovarian cancer is the most common form of ovarian cancer. The researchers said they used a combination therapy in this study that might be effective in treating 50% of patients with ovarian cancer.
In the article, the researchers developed a combination therapy with the drug carboplatin in combination with a drug called birinapant, which can significantly improve the survival rate of ovarian cancer mice. In addition, the study also found that by detecting a specific protein It is possible to identify ovarian tumors that can be effectively treated, and more importantly, this new type of therapy can target cancers in other parts of the body, including colon, bladder, cervical and lung cancers.
The researchers first tested whether this combination therapy could improve the survival rate of mice. Half of the tested mice carried human ovarian tumors resistant to carboplatin, while the other half of the mice carried pairs. In carboplatin-sensitive tumors, the researchers treated mice with carboplatin or birinapant, and treated the mice with a combination of the two drugs, followed by continuous monitoring of the mice, when the drug carboplatin or birinapant affected the mice. At a lower level, combination therapy can double the overall survival of half of the mice (study subjects) regardless of whether these mice are sensitive or resistant to carboplatin.
Researcher Rachel Fujikawa said that our results suggest that this therapy is only applicable in some tumors; to assess the effectiveness of this combination therapy in treating tumors, the researchers then applied 23 of the non-dependent patient bodies. High-grade serous ovarian cancer was tested, and some samples were from patients who had never been treated with carboplatin, and some from patients who were resistant to carboplatin. The results show that this new combination therapy can eliminate ovarian tumors in nearly 50% of the samples, and more importantly, this combination therapy can also have a therapeutic effect on carboplatin-resistant tumors and sensitive tumors.
The researchers then determined the level of cIAPs in the tumor, cIAPs are the target of the drug birinapant, the researchers found that there is a strong correlation between cancer stem cells carrying high levels of cIAPs and positive effects on combination therapy, due to elevated levels of cIAPs and Other cancers are directly related to chemoresistance, so researchers want to know if combination therapy can effectively treat other types of cancer. At the same time, the researchers also used cancer cells such as human bladder cancer cells and lung cancer cells to construct a cultured disease model, and tested with this new type of therapy. The results showed that 50% of the tumors can be targeted and at the same time higher levels. The positive response of cIAPs and tumor tissue to combination therapy is directly related.
The final researcher, Memarzadeh, said the study could help us develop a new treatment. In future research, we hope to have a 1/2-stage clinical trial of ovarian cancer patients who are predicted to benefit from combination therapy. .
Source: Bio Valley
Stomach tube,feeding tube,gastric tube,ng tube
2 MEDS TECHONOLOGY CO.,LTD , https://www.2-meds.com